Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DFFN
Previous Symbol
CUSIPN/A
Phone434-220-0718
Debt
Debt-to-Equity RatioN/A
Current Ratio20.15
Quick Ratio20.15
Price-To-Earnings
Trailing P/E Ratio-0.30
Forward P/E Ratio-0.82
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash Flow$0.1835 per share
Price / Cash1.88
Book Value$0.42 per share
Price / Book0.82
Profitability
EPS (Most Recent Fiscal Year)($1.14)
Net Income$-1,360,000.00
Net MarginsN/A
Return on Equity-36.05%
Return on Assets-25.90%
Miscellaneous
Employees11
Outstanding Shares50,570,000
Market Cap$16.74 million
OptionableNot Optionable
Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions
What is Diffusion Pharmaceuticals' stock symbol?
Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."
How were Diffusion Pharmaceuticals' earnings last quarter?
Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) announced its quarterly earnings results on Monday, August, 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. View Diffusion Pharmaceuticals' Earnings History.
What price target have analysts set for DFFN?
1 analysts have issued 12-month target prices for Diffusion Pharmaceuticals' shares. Their forecasts range from $1.25 to $1.25. On average, they expect Diffusion Pharmaceuticals' stock price to reach $1.25 in the next year. This suggests a possible upside of 267.6% from the stock's current price. View Analyst Price Targets for Diffusion Pharmaceuticals.
What is the consensus analysts' recommendation for Diffusion Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diffusion Pharmaceuticals.
Has Diffusion Pharmaceuticals been receiving favorable news coverage?
News coverage about DFFN stock has been trending neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Diffusion Pharmaceuticals' key competitors?
Some companies that are related to Diffusion Pharmaceuticals include Alpine Immune Sciences (ALPN), Bellerophon Therapeutics (BLPH), Vistagen Therapeutics (VTGN), Sophiris Bio (SPHS), Oncomed Pharmaceuticals (OMED), Leap Therapeutics (LPTX), Humanigen (HGEN), GT Biopharma (GTBP), Fortress Biotech (FBIO), Clearside Biomedical (CLSD), Merrimack Pharmaceuticals (MACK), Neurotrope (NTRP), Aquinox Pharmaceuticals (AQXP), Helix Biopharma (HBPCF) and Trevena (TRVN).
Who are Diffusion Pharmaceuticals' key executives?
Diffusion Pharmaceuticals' management team includes the folowing people:
- Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 69)
- Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 79)
- Mr. William Karl Hornung, Chief Financial Officer (Age 49)
- Mr. Thomas E. Byrne, Gen. Counsel (Age 61)
- Dr. David Randolph Jones M.D., Chief Medical Officer (Age 55)
How do I buy shares of Diffusion Pharmaceuticals?
Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Diffusion Pharmaceuticals' stock price today?
One share of DFFN stock can currently be purchased for approximately $0.34.
How big of a company is Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals has a market capitalization of $16.74 million. The company earns $-1,360,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Diffusion Pharmaceuticals employs 11 workers across the globe.
What is Diffusion Pharmaceuticals' official website?
How can I contact Diffusion Pharmaceuticals?
Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]
MarketBeat Community Rating for Diffusion Pharmaceuticals (NASDAQ DFFN)
MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote "Outperform" if you believe DFFN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days.
